ReviewEchocardiography (Mount Kisco, N.Y.)2026
Multimodal Echocardiographic Assessment in Intravenous Immunoglobulin-Resistant Kawasaki Disease: From Prediction to Long-Term Surveillance.
Review in Echocardiography (Mount Kisco, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Kawasaki disease (KD) with intravenous immunoglobulin (IVIG) non-response is a high-risk state in which fever response, coronary evolution, and myocardial dysfunction may diverge. This narrative review, appraised against SANRA after drafting, examines echocardiography across the disease-management lifecycle, from pre-treatment risk enrichment to long-term surveillance. PubMed/MEDLINE searches were supplemented by cross-source discovery and metadata verification. Standardized serial coronary measurement with consistent use of one Z-score system remains the management core. Initial composite echocardiographic abnormalities, myocardial deformation, and tissue-Doppler indices may enrich risk assessment, but current discrimination is moderate and thresholds lack external validation. IVIG non-response and coronary aneurysm are related but non-interchangeable; defervescence does not establish coronary safety, whereas definite baseline coronary artery aneurysm is a treatment-relevant high-risk phenotype. Deformation, myocardial work, right-heart indices, coronary flow reserve, and complementary imaging can refine selected clinical questions but should not trigger treatment in isolation. Echocardiography can therefore structure coronary and myocardial surveillance, but cannot yet independently determine treatment resistance or support a universal multimodal treatment score. Prospective multicenter standardization, external validation, and clinical-utility testing are required before multimodal imaging-guided treatment decisions are adopted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.